Bank of New York Mellon’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-12,755
| Closed | -$19.1K | – | 4500 |
|
|
2023
Q1 | $19.1K | Hold |
12,755
| – | – | ﹤0.01% | 4310 |
|
|
2022
Q4 | $12.7K | Hold |
12,755
| – | – | ﹤0.01% | 4399 |
|
|
2022
Q3 | $23K | Hold |
12,755
| – | – | ﹤0.01% | 4435 |
|
|
2022
Q2 | $37K | Sell |
12,755
-90,715
| -88% | -$263K | ﹤0.01% | 4415 |
|
|
2022
Q1 | $285K | Sell |
103,470
-7,893
| -7% | -$21.7K | ﹤0.01% | 4037 |
|
|
2021
Q4 | $519K | Buy |
111,363
+4,021
| +4% | +$18.7K | ﹤0.01% | 3793 |
|
|
2021
Q3 | $913K | Sell |
107,342
-8,550
| -7% | -$72.7K | ﹤0.01% | 3438 |
|
|
2021
Q2 | $1.9M | Sell |
115,892
-9,188
| -7% | -$151K | ﹤0.01% | 3008 |
|
|
2021
Q1 | $2.76M | Sell |
125,080
-285
| -0.2% | -$6.29K | ﹤0.01% | 2740 |
|
|
2020
Q4 | $3.88M | Buy |
125,365
+47,689
| +61% | +$1.47M | ﹤0.01% | 2479 |
|
|
2020
Q3 | $1.58M | Buy |
77,676
+23,086
| +42% | +$469K | ﹤0.01% | 2808 |
|
|
2020
Q2 | $839K | Buy |
54,590
+13,115
| +32% | +$202K | ﹤0.01% | 3207 |
|
|
2020
Q1 | $321K | Hold |
41,475
| – | – | ﹤0.01% | 3569 |
|
|
2019
Q4 | $592K | Buy |
41,475
+12,412
| +43% | +$177K | ﹤0.01% | 3505 |
|
|
2019
Q3 | $437K | Buy |
+29,063
| New | +$437K | ﹤0.01% | 3599 |
|